Srimathi Srinivasan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Pseudomonas Aeruginosa

Tyrosine Kinase

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Nora D Mineva, Stefania Pianetti, Sonia G Das, Srimathi Srinivasan, Nicolas M Billiald, Gail E Sonenshein
A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. Pharmaceutics 16 (4) (2024)
Nora D Mineva, Stefania Pianetti, Sonia G Das, Srimathi Srinivasan, Nicolas M Billiald, Gail E Sonenshein
A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. Pharmaceutics 16 (4) (2024)
Alan Cooper, Sravya Tumuluru, Kyle Kissick, Girish Venkataraman, Joo Y Song, Andrew Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander V Bagaev, Brendan Hodkinson, Srimathi Srinivasan, Sonali M Smith, David W Scott, Christian Steidl, James K Godfrey, Justin Kline
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Aatman S Doshi, Susan Cantin, Marylens Hernandez, Srimathi Srinivasan, Sharon Tentarelli, Matthew Griffin, Yanjun Wang, Petar Pop-Damkov, Laura B Prickett, Cecilia Kankkonen, Minhui Shen, Maryann San Martin, Song Wu, M Paola Castaldi, Hormas Ghadially, Jeffrey Varnes, Sonya Gales, David Henry, Clare Hoover, Deanna A Mele, Iain Simpson, Eric T Gangl, Scott N Mlynarski, M Raymond V Finlay, Lisa Drew, Stephen E Fawell, Wenlin Shao, Alwin G Schuller
Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners. Molecular cancer therapeutics (2023)
Tahla Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P Kater
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)